Senti Bio reports positive AML clinical results, durable remission rates, and strong safety profile.

Senti Bio presented data at the American Society of Hematology (ASH) meeting, showing deep and durable clinical remission rates for SENTI-202 in treating relapsed/refractory Acute Myeloid Leukemia (AML). The data also highlighted a strong safety profile and pharmacodynamic results that underscore the clinical proof-of-mechanism for the 'OR/NOT' Logic Gate. Senti Bio's Logic Gate technology has the potential to overcome a central challenge in treating cancers, achieving selective cancer killing and healthy tissue sparing.